Early adoption of injectable naltrexone for alcohol-use disorders: findings in the private-treatment sector.
OBJECTIVE
The U.S. substance-abuse treatment system has been slow to adopt medications for the treatment of alcohol-use disorders (AUDs). The objectives of this study are to (a) determine how the inherent characteristics of injectable naltrexone (i.e., relative advantage, complexity, trialability, observability, compatibility) shape organizational-level decisions to adopt the medication and (b) identify key predictors of adoption and barriers that impede adoption.


METHODS
This study uses data from a nationally representative sample of 345 privately funded U.S. substance-abuse treatment programs to examine adoption (current use) of injectable naltrexone.


RESULTS
Sixteen percent of private treatment programs are early adopters of injectable naltrexone. Multivariate logistic regression models reveal that organizational size and percentage of patients paying with private insurance are significant predictors of adoption. The most salient predictor of adoption is innovation compatibility, measured by program use of other AUD pharmacotherapies. Barriers to adoption include cost, lack of access to prescribing physicians, and lack of knowledge about the medication. Injectable naltrexone, however, is addressing the patient compliance barrier, demonstrated by 70% of patients receiving at least 2 months of medication.


CONCLUSIONS
The adoption of AUD pharmacotherapies remains low, with only half of the sampled programs prescribing any AUD pharmacotherapies. Patterns of early adoption of injectable naltrexone are, however, promising. Results highlight innovation compatibility and relative advantage as explanations of organizational decisions to adopt injectable naltrexone. Future research will move beyond issues of adoption and provide a more detailed examination of the implementation process.
Abraham
Amanda J
AJ
Institute for Behavioral Research, 112 Barrow Hall, University of Georgia, Athens, Georgia 30602-2401, USA. aabraham@uga.edu
Roman
Paul M
PM
D000427:Alcohol Deterrents / Q000008:administration & dosage / Q000627:therapeutic use*; D019973:Alcohol-Related Disorders / Q000534:rehabilitation*; D003625:Data Collection; D004059:Diffusion of Innovation; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D007267:Injections; D016015:Logistic Models; D055118:Medication Adherence; D015999:Multivariate Analysis; D009271:Naltrexone / Q000008:administration & dosage / Q000627:therapeutic use*; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data; D017149:Private Sector; D016320:Substance Abuse Treatment Centers / Q000706:statistics & numerical data; D014481:United States
D000427:Alcohol Deterrents; D009271:Naltrexone
J Subst Abuse Treat. 2002 Jun;22(4):211-8
12072165
Drug Alcohol Depend. 2003 Sep 10;71(3):219-28
12957340
J Subst Abuse Treat. 2008 Jun;34(4):433-42
17997266
Alcohol Clin Exp Res. 2004 Aug;28(8):1229-35
15318122
J Subst Abuse Treat. 2003 Jan;24(1):1-11
12646325
Health Serv Res. 2008 Jun;43(3):951-70
18454775
J Subst Abuse Treat. 2004 Jan;26(1):353-61
14698799
J Subst Abuse Treat. 2008 Oct;35(3):260-8
18329227
Addiction. 2008 Nov;103(11):1801-8
19032530
Am J Psychiatry. 2005 Aug;162(8):1423-31
16055763
J Stud Alcohol Drugs. 2007 Nov;68(6):852-61
17960303
Psychiatr Serv. 2004 Mar;55(3):221
15001719
Addiction. 2003 May;98(5):617-26
12751979
J Clin Psychopharmacol. 2007 Oct;27(5):507-12
17873686
Alcohol Clin Exp Res. 2004 Jul;28(7):1051-9
15252291
Alcohol Alcohol. 2007 Mar-Apr;42(2):113-8
17172258
J Subst Abuse Treat. 2009 Jan;36(1):1-6
18775624
Drug Alcohol Depend. 2007 Mar 16;87(2-3):164-74
16971059
JAMA. 2005 Apr 6;293(13):1617-25
15811981
J Clin Psychopharmacol. 2006 Dec;26 Suppl 1:S13-9
17114950
J Subst Abuse Treat. 2005 Apr;28(3):273-80
15857728